Fox Run Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Fox Run Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1M	Buy	+38,178	New	+$889K	0.17%	183
2026 Q1	–	Sell	-36,736	Closed	-$1.07M	–	900
2025 Q4	$1.07M	Buy	36,736 +7,887	+27%	+$202K	0.16%	187
2025 Q3	$544K	Buy	28,849 +17,582	+156%	+$277K	0.08%	461
2025 Q2	$158K	Sell	11,267 -18,700	-62%	-$262K	0.03%	774
2025 Q1	$469K	Buy	29,967 +13,021	+77%	+$183K	0.07%	523
2024 Q4	$236K	Sell	16,946 -2,384	-12%	-$26.1K	0.04%	715
2024 Q3	$180K	Sell	19,330 -9,509	-33%	-$93.8K	0.04%	683
2024 Q2	$268K	Buy	+28,839	New	+$261K	0.05%	580
2023 Q4	–	Sell	-11,216	Closed	-$59.6K	–	719
2023 Q3	$59.6K	Buy	+11,216	New	+$95.4K	0.02%	656

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Fox Run Management's ARQT Position: Q2 2026 in Review

Fox Run Management opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 38,178 shares worth $1M. The stake represents 0.17% of the portfolio and ranks #183 among its holdings. This is a return to the name: Fox Run Management previously reported a position in ARQT as recently as Q4 2025.

Fox Run Management first reported a position in ARQT in Q3 2023 and has held it in 9 quarters since. The position peaked at $1.07M in Q4 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Fox Run Management held 38,178 shares of Arcutis Biotherapeutics worth $1M as of Q2 2026.
Arcutis Biotherapeutics was a new Fox Run Management position in Q2 2026.
Arcutis Biotherapeutics made up 0.17% of Fox Run Management's portfolio in Q2 2026, its #183 holding.
Fox Run Management first reported a position in Arcutis Biotherapeutics in Q3 2023 and has held it in 9 quarters since.
Fox Run Management's Arcutis Biotherapeutics position peaked at $1.07M in Q4 2025.
273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.